{"brief_title": "Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)", "brief_summary": "The primary purpose of the study is to determine if patients with brain metastases from non-small cell lung cancer treated with Motexafin Gadolinium and whole brain radiation therapy retain their neurologic function and ability to think for a longer time compared to patients treated with whole brain radiation therapy alone.", "condition": "Metastases, Neoplasm", "intervention_type": "Drug", "intervention_name": "Motexafin Gadolinium", "criteria": "Inclusion Criteria: - Adults (\u226518 years old) with radiologically proven parenchymal brain metastases from histologically confirmed non-small cell lung cancer; - KPS score of \u226570; - Each patient must sign a study-specific Informed Consent form Exclusion Criteria: - Liver metastases; - Extracranial metastases in two or more organs; - Known leptomeningeal metastases or subarachnoid spread of tumor; - Prior whole brain radiation; - Plan to use radiosurgery or radiation boost after completion of WBRT; - Planned chemotherapy during study treatment (prior and subsequent chemotherapy is allowed); - Prior total resection of a single brain metastasis; - Laboratory values as follows: LDH > 1.3 x upper limit of normal (ULN); ANC < 1500 /mm\u00b3; Platelets < 50,000 /mm\u00b3; Creatinine > 2.0 mg/dL; AST or ALT > 2 x ULN; Total bilirubin > 2 x ULN; - Women who are pregnant or lactating", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00054795.xml"}